For 21 years, Sebastien Beauzile lived with a disease that shaped every part of his existence.
Chronic pain, hospital stays, a body that could not be trusted, and a future that felt permanently limited.
Doctors at Cohen Children’s Medical Center on Long Island gave him a single infusion that changed all of that.
Beauzile has become the first person in New York State to be cured of sickle cell anemia, using a gene therapy called Lyfgenia that reprogrammed his own bone marrow to produce healthy red blood cells for the first time in his life.
“Since gene therapy, I haven’t had any pain,” he said.
“I’m finding I can do things that I couldn’t do before.”
His words are not just a personal milestone.
They represent a turning point in the history of a disease that has been described in medical literature since 1910, and for most of that time has had no cure at all.
What Sickle Cell Disease Actually Does
To understand why this breakthrough matters, it helps to understand exactly what sickle cell disease takes from the people who have it.
Sickle cell disease is an inherited blood disorder caused by a mutation in the gene responsible for producing haemoglobin, the protein inside red blood cells that carries oxygen throughout the body.
In a healthy person, red blood cells are round, flexible, and disc-shaped.
They move easily through blood vessels and deliver oxygen efficiently to every organ and tissue.
In a person with sickle cell disease, the haemoglobin molecule is structurally abnormal.
Under certain conditions, it causes red blood cells to collapse into a rigid, crescent or sickle shape.
These misshapen cells do not bend.
They get stuck.
They clog blood vessels, blocking the flow of oxygen to tissues and organs.
The result is what doctors call a vaso-occlusive crisis, an episode of severe, sometimes unbearable pain that can last for hours or days and strike without warning.
Over a lifetime, these crises cause cumulative damage to the lungs, kidneys, eyes, bones, and brain.
They increase the risk of stroke.
They shorten life expectancy.
According to the CDC, sickle cell disease affects approximately one in every 365 Black infants born in the United States.
It affects an estimated 100,000 Americans overall, with 90% of those patients being Black.
Globally, it is one of the most common serious genetic disorders on earth.
And until very recently, the medical toolkit for treating it was almost entirely limited to managing symptoms, not eliminating the disease.
How the Study Was Conducted
The treatment that cured Sebastien Beauzile is called Lyfgenia, developed by biotech company Bluebird Bio and approved by the FDA in December 2023.
It belongs to a category of medicine known as gene therapy, and its approach is both conceptually elegant and technically demanding.
The process begins with the patient’s own body.
Doctors collect stem cells from Beauzile’s bone marrow, the spongy tissue inside bones where all blood cells are produced.
These stem cells are extracted and sent to a specialist laboratory, where they are genetically modified using a technique called gene addition.
A corrective gene is inserted into the stem cells, programming them to produce a modified form of haemoglobin called HbAT87Q, which functions like normal adult haemoglobin and prevents red blood cells from taking on the sickle shape.
Before the modified cells can be reintroduced, the patient undergoes a course of high-dose chemotherapy, called myeloablative conditioning, to clear out the bone marrow and make room for the corrected cells.
The modified stem cells are then infused back into the body through an intravenous drip.
Over the following six to eight weeks, the corrected cells take up residence in the bone marrow and begin producing healthy, normally shaped red blood cells.
According to data from the clinical trial, the therapy resulted in a complete resolution of symptoms within 6 to 18 months in 88% of trial participants.
For Beauzile, the process worked exactly as intended.
Findings From the Study
Beauzile received his infusion on December 17, 2024, at Cohen Children’s Medical Center, the same hospital he had been attending since he was two months old.
He had known the corridors of that building for his entire life.
This time, he left it as the first person in New York history to be cured of the disease that had defined those visits.
“Sickle cell was like a blockade for me,” he told CBS News, “but now it’s just like a wall that I just jumped over.”
Dr. Jeffrey Lipton, one of the physicians involved in his care, placed the achievement in its full historical context: “Sickle cell disease was described in modern medicine in 1910, and here we are over 100 years later, and this is the first cure you are seeing.”
Beauzile’s mother, Magda Lamour, who had watched her son suffer for two decades, said there were not enough words to express her gratitude to the medical team.
Since receiving the treatment, Beauzile has experienced no pain whatsoever. He is looking forward to travelling, working out, and focusing on his education, with hopes of working in the medical field.
“I feel unstoppable,” he said.
A Hospital Already Leading the Way
Cohen Children’s Medical Center, part of Northwell Health’s network on Long Island, did not arrive at this achievement by accident.
The hospital was also the first in New York to administer Zynteglo, another recently approved gene therapy, to an eight-year-old boy to treat his beta-thalassemia, a related blood disorder.
In December 2025, the same hospital became the first in New York State to administer Casgevy, a separate gene therapy for sickle cell disease developed by Vertex Pharmaceuticals and CRISPR Therapeutics, and the first treatment in history to use the gene editing tool CRISPR to receive FDA approval.
The two therapies take different scientific approaches but reach the same destination.
Casgevy uses gene editing to switch off a gene that suppresses foetal haemoglobin production, allowing the body to produce a form of haemoglobin that naturally resists sickling. Lyfgenia uses gene addition to insert a corrective gene directly.
Both represent a fundamental shift from managing sickle cell disease to eliminating it at its genetic root.
The Science Behind the Breakthrough
The reason these therapies can work at all is rooted in a remarkable insight about haemoglobin biology.
Human beings actually produce two types of haemoglobin over the course of their lives.
Before birth and in infancy, the body produces foetal haemoglobin, which binds oxygen more efficiently than the adult version and is not affected by the sickle cell mutation.
After birth, a genetic switch flips and the body begins producing adult haemoglobin instead.
In people with sickle cell disease, it is this adult haemoglobin that carries the fatal mutation.
Casgevy works by editing the gene that controls this switch, preventing it from shutting off foetal haemoglobin production.
Lyfgenia works by inserting a corrective version of the haemoglobin gene directly, providing the body with a working template it was never born with.
The modified stem cells produce HbAT87Q, a gene-therapy-derived haemoglobin that functions similarly to normal adult haemoglobin. Red blood cells carrying HbAT87Q are far less likely to sickle and obstruct blood flow.
The science is the product of decades of haematology research, years of clinical trials, and an enormous collaborative effort across medicine, biotechnology, and regulatory institutions.
It works.
The Obstacle Nobody Wants to Talk About
Here is where the story becomes more complicated, and where honest reporting requires acknowledging something important.
The cure for sickle cell disease now exists.
For a large proportion of the people who need it most, it remains entirely out of reach.
Lyfgenia carries a list price of $3.1 million. Casgevy lists for $2.2 million.
These are not insurance co-pays.
They are the sticker prices for a single treatment.
The manufacturers argue, with some mathematical legitimacy, that the lifetime cost of managing sickle cell disease through hospitalisations, medications, and organ damage repair can reach four to six million dollars per patient.
A one-time cure, on that basis, may actually save money over a lifetime.
But that argument requires an insurance system capable of absorbing a multi-million dollar upfront cost, and a patient who can navigate the administrative labyrinth between diagnosis and treatment.
Two years after FDA approval, just 64 patients with sickle cell disease received infusions of Casgevy in 2025, while Lyfgenia had treated just over 100 patients in total since its launch.
In a country with an estimated 100,000 sickle cell patients, those numbers are sobering.
Patient advocates have reported that doctors who see sickle cell patients regularly are discouraging them from pursuing gene therapy, and that education gaps among healthcare providers remain a significant barrier to uptake.
The chemotherapy required to prepare patients for treatment carries its own serious risks, including a significant likelihood of infertility, a concern that weighs heavily for patients in their teens and twenties.
And the process is not quick.
From initial cell collection to infusion to recovery, the treatment journey takes months of intensive medical care, requiring extended time away from work, school, and family, and access to one of a limited number of specialist centres equipped to deliver it.
A Disease That Has Long Been Neglected
It is impossible to discuss access to sickle cell treatment without addressing who the disease affects.
In the United States, 90% of sickle cell disease patients are Black.
The disease has historically received far less research funding and clinical attention than conditions with comparable or smaller patient populations that more often affect white Americans.
Despite levodopa having been available as a treatment for Parkinson’s disease since the late 1960s, as recently as 2025 most of the world’s sickle cell patients faced similar barriers in accessing even the most basic treatments available for their own condition.
The arrival of a genuine cure for sickle cell disease, more than a century after it was first described in medical literature, is an extraordinary scientific achievement.
The gap between that achievement and the patients who need it most is a test of something other than science.
What Comes Next
The agencies and companies involved are aware of the access problem and are working, with varying degrees of urgency, to address it.
In January 2025, the Centers for Medicare and Medicaid Services launched the Cell and Gene Therapy Access Model, a voluntary programme designed to help state Medicaid agencies negotiate outcomes-based payment agreements for sickle cell gene therapies, linking reimbursement to how well patients actually do after treatment.
Both Vertex and Bluebird Bio have entered the programme, and states can begin participation on a rolling basis.
Meanwhile, researchers are already working on the next generation of treatments that could eventually bypass some of the current barriers.
Tessera Therapeutics is developing an in vivo gene writing therapy for sickle cell disease that would directly correct the mutation inside the patient’s body, without the need to extract, modify, and reinfuse stem cells. The Bill and Melinda Gates Foundation invested $50 million in the programme in December 2024.
An in vivo approach, if it succeeds, would eliminate the need for bone marrow extraction, the conditioning chemotherapy, and the lengthy treatment journey that currently makes access so difficult.
It would bring the cure closer to the patient, rather than requiring the patient to travel to the cure.
For Sebastien Beauzile, those future developments are someone else’s chapter.
His chapter has already been written.
After 21 years of pain, of hospitals, of uncertainty, he walked out of Cohen Children’s Medical Center with a body that works the way it was always supposed to.
The disease that had defined his life since he was two months old is gone.
He is, in his own words, unstoppable.
The Global Scale of What Has Been Cured
Sebastien Beauzile’s story is remarkable precisely because it is so rare.
And that rarity is itself the story.
Approximately 300,000 infants are born with sickle cell disease every year, with Africa experiencing the highest incidence of all.
Up to 2% of the populations of Nigeria, India, and the Democratic Republic of the Congo have the disease, and these three countries account for 90% of the global sickle cell burden.
Nigeria alone records approximately 150,000 new sickle cell births annually, making it the country with the highest prevalence of the disease on earth.
To put those numbers next to the number of people who have received the gene therapies that now exist is to confront an uncomfortable reality directly.
In countries across sub-Saharan Africa, sickle cell disease contributes up to 7 to 16% of all deaths in children under five years old.
These are not elderly patients dying at the end of a long life managed by medication.
These are children.
Children dying from a disease that a hospital on Long Island has now demonstrated it can cure.
The gap between what medicine can do and what most patients can actually access has rarely been more stark.
A Disease That Was Never Treated as a Priority
The history of sickle cell disease research is inseparable from the history of how medicine has valued the lives of the people most affected by it.
Sickle cell disease was first described in the scientific literature in 1910.
For most of the century that followed, it received a fraction of the research investment directed at conditions affecting predominantly white populations with comparable or smaller patient numbers.
Advocacy groups and medical researchers have documented this disparity for decades, and it is directly reflected in the treatment timeline.
The gene therapies that can now cure the disease were not approved until December 2023, more than 113 years after the condition was first identified.
Cystic fibrosis, a genetic disease that primarily affects white patients of Northern European descent and has a significantly smaller global patient population, had disease-modifying therapies approved decades earlier and a far more robust pharmaceutical pipeline throughout its history.
The comparison is not comfortable, but it is accurate, and it matters for understanding why the cure arriving in a New York hospital in 2024 feels like both a triumph and an indictment simultaneously.
What Real Equity in Access Would Look Like
The doctors and advocates working in this field are clear about what genuine equitable access to these therapies would require.
It begins with the basics that wealthy nations take for granted.
The Lancet Haematology Commission has recommended that by 2025, policies, resources, and facilities should be in place to allow all babies worldwide to be screened for sickle cell disease at birth.
Newborn screening is the essential foundation.
Without it, many patients in high-burden countries are not diagnosed until they have already experienced organ damage, pain crises, or life-threatening complications.
You cannot treat a disease you have not identified.
Many countries across sub-Saharan Africa still have no or limited newborn screening programmes.
Even where diagnosis exists, treatment access is patchy at best.
The most basic interventions, penicillin prophylaxis to prevent bacterial infections in young children, hydroxyurea to reduce pain crises, and blood transfusions for acute complications, are inconsistently available across the regions where sickle cell disease is most prevalent.
Against that backdrop, the prospect of a three-million-dollar gene therapy reaching the communities that carry the greatest burden of this disease is not simply a question of insurance coverage and payment models.
It is a question of global health infrastructure, political will, and the degree to which the international medical community treats patients in Lagos and Kinshasa with the same urgency it treats patients in New Hyde Park.
Civil rights attorney Ben Crump, who announced a $100,000 donation to Northwell Health in recognition of Beauzile’s treatment, framed the broader challenge plainly.
The cure is not enough.
The cure has to reach the people who need it.
A Moment That Deserves Its Full Weight
Sebastien Beauzile called his treatment day his new birthday.
He celebrated with his medical team, the same people who had been treating him since he was two months old, and he thanked them with words that fell short of what he was feeling, because some things are beyond language.
His doctors, for their part, were equally aware of what they were witnessing.
One of them pointed out that sickle cell disease has been known to medicine for more than a century.
That the first person in New York to be cured of it is a 21-year-old Black man from Long Island, who spent his entire childhood and adolescence in and out of hospital, is a fact that carries a particular weight.
It is a story about what medicine can achieve when it finally decides to try.
It is also a reminder of how long that trying was delayed, and how many people suffered and died while the tools that could have helped them waited to be built.
The cure exists now.
Sebastien Beauzile is proof of it.
The question the world must now answer is whether his story will remain a milestone or become a beginning.
Sources: CBS News New York | Northwell Health Cohen Children’s Lyfgenia | Northwell Health Casgevy December 2025 | Pharmacy Times | BioSpace Gene Therapy Uptake 2026 | Frontiers in Hematology Global SCD Burden | Nature Communications Medicine Africa SCD | Sickle Cell Disease Association of America | STAT News on Access
